Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer
ConclusionNeoadjuvant therapy is associated with enhanced survival in patients with borderline-resectable pancreatic cancer, which may be attributed to tumor downstaging.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Borderline Tumor | Cancer | Cancer & Oncology | Databases & Libraries | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer